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Abstract
Burning mouth syndrome (BMS) is a neuropathic pain disorder associated with a burning 
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paraesthetic sensations. However, patients present no clinically evident causative lesions. The poor 
classification of the disorder has resulted in a diagnostic challenge, particularly for the 
clinician/dentist evaluating these individuals. Major research developments have been made in the 
BMS field in recent years to address this concern, principally in terms of the pathophysiological 
mechanisms underlying the disorder, in addition to therapeutic advancements. For the purpose of 
this review, an update on the pathophysiological mechanisms will be discussed from a 
neuropathic, immunological, hormonal and psychological perspective. This review will also focus 
on the many therapeutic strategies that have been explored for BMS, including 
antidepressants/antipsychotics, nonsteroidal anti-inflammatories, hormone replacement therapies, 
phytotherapeutic compounds and non-pharmacological interventions, overall highlighting the lack 
of controlled clinical studies to support the effectiveness of such therapeutic avenues. Particular 
focus is given to the cannabinoid system, and the potential of cannabis-based therapeutics in 
managing BMS patients.
1. Introduction
Primary, or idiopathic burning mouth syndrome (BMS), is defined by the International 
Headache Society as an “intraoral burning or dysaesthetic sensation, recurring daily for more than 
two hours per day over more than three months, without clinically evident causative lesions”. In 
addition to the oral burning or stinging sensation of the tongue, lips or other oral mucosal surfaces, 
BMS patients frequently report dry mouth (xerostomia), taste disturbance (dysgeusia) and tingling 
or paraesthetic sensations (IHS, 2018). Although some reports indicate a decrease in unstimulated 
salivary flow in BMS (Lee et al., 2015), recent data suggest that the alteration in both 
unstimulated and stimulated salivary flow is associated with the medication used by the patient(s), 
and the presence of other systemic diseases, rather than the syndrome per se (Acharya et al., 
2018b). Moreover, Lee et al. (2015) did not identify significant differences in salivary gland 
function when using salivary scintigraphy. According to ICD-10 codes, BMS is also known as 
glossodynia, orodynia, stomatodynia, and sore or burning tongue, and is currently described by the 
International Headache Society as a “painful cranial neuropathy”, highlighting the neuropathic 
mechanisms underlying the disorder. BMS was previously viewed as a “psychogenic pain” due to 
its close association with psychological factors including anxiety, depression and carcinophobia 
(Browning et al., 1987). This shift in classification has been increasingly supported by data from 
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provide evidence of neuropathic alterations in BMS patients, as reviewed extensively elsewhere 
(Jaaskelainen & Woda, 2017). A secondary BMS may also occur due to local (candidiasis, lichen 
planus, hyposalivation) or systemic (medication-induced, anaemia, deficiencies of vitamin B12 or 
folic acid, Sjögren’s syndrome, diabetes) causes. In the case of secondary BMS, once the 
underlying factors are treated, the symptoms cease (IHS, 2018). Primary BMS is the focus of this 
review.
1.1.  Clinical features of BMS
The clinical features of BMS vary from patient to patient, including variations in pain 
intensity and duration. The onset of symptoms can be gradual or sudden, with no identifiable 
trigger. However, some cases have been linked to dental procedures, trauma, new medication use, 
illness or stressful life events (Bender, 2018). In most cases the pain progresses from mild to 
moderate throughout the day (Lopez-Jornet et al., 2015b), and may be continuous or intermittent, 
most commonly affecting the anterior two-thirds of the tongue; however, the pain may impact 
other mucosal surfaces. Furthermore, the symptoms tend to be bilateral and symmetric (Wada et 
al., 2017; Bender, 2018). Based on these differences, some authors have classified different 
subtypes of BMS (Moghadam-Kia & Fazel, 2017), nonetheless no clear classification has been 
validated to date. More recent reports to divide BMS into three major categories depending on the 
neuropathic origin of the disorder include the following: (i) peripheral small fiber neuropathy, (ii) 
trigeminal neuropathy, and (iii) hypofunction of dopaminergic neurons in the basal ganglia 
(Jaaskelainen & Woda, 2017).
Several factors can modify the painful symptoms reported in BMS, including the consumption 
of food/drink, speech (Bender, 2018) and sleep quality (Lopez-Jornet et al., 2015a). Even though 
some patients report pain relief while eating, most patients avoid hot, spicy, acidic food/drinks or 
alcoholic beverages, since they intensify the pain sensation (Bender, 2018). Poor sleep quality is 
frequently reported in BMS and correlates with syndrome severity (Adamo et al., 2018). 
Furthermore, stress and fatigue have a major impact on pain intensity, and the disruption of the 
circadian rhythm can affect inflammation (Kizaki et al., 2015), pain thresholds and pain sensitivity 










This article is protected by copyright. All rights reserved
1.2.  Diagnosis of BMS
The diagnosis of primary BMS is a clinical challenge and can only be established by exclusion 
of other disorders that may cause oral cavity pain (Moghadam-Kia & Fazel, 2017; Bender, 2018), 
in particular Sjögren’s syndrome (Aljanobi et al., 2017). A clinical evaluation is made when the 
pain complaints are consistent with the oral burning pain sensation, and there is no physical 
pathology associated with the complaint. To establish a diagnosis, the clinician must gather a 
comprehensive medical and dental history, detailing the characteristics of the pain (onset, 
duration, anatomical location, exacerbating/ameliorating factors), current medication use, 
coexisting manifestations of xerostomia, denture use and history of psychiatric disease (anxiety 
disorder, depression, personality disorder). A history of previous upper respiratory tract infections, 
middle ear disease or surgery associated with damage to the chorda tympani nerve (branch of 
cranial nerve VII) should also be recorded (Bender, 2018). This is particularly relevant since taste 
input mediated by the chorda tympani nerve is known to inhibit the trigeminal somatic input at the 
central nervious system (CNS). Therefore, BMS may result from the loss of the normal chorda 
tympani inhibitory control over somatic afferents, thus intensifying trigeminal sensations 
including pain (Bartoshuk et al., 2005). A physical evaluation should also investigate signs of 
parafunctional habits, erythema, irritation, mucosal ulceration or other abnormalities. Furthermore, 
laboratory studies should collate blood cell counts, iron, zinc and vitamin levels, fasting blood 
glucose levels/glycosylated haemoglobin and thyroid function (Moghadam-Kia & Fazel, 2017; 
Bender, 2018).
Due to difficulties in diagnosing BMS, patients commonly attend several clinical consultations 
prior to a definitive diagnosis, resulting in delays in treatment initiation and commonly 
exacerbating anxiety. Hence, further characterization of BMS is needed, in addition to clear 
diagnostic tools. This is particularly relevant taking into consideration the older age demographic 
of BMS patients, usually with multimorbidity and polypharmacy that increases the risk of adverse 
drug effects commonly associated with the symptoms of BMS (hyposalivation, dysgeusia) (Ni 
Riordain et al., 2019). With that aim, several attempts have been made to identify specific 
biomarkers for the disorder. Indeed, some promising candidates include interleukin (IL)-18 (a pro-
inflammatory cytokine associated with interferon-gamma (IFN-) synthesis (Banu et al., 2015)), 
kallikrein (Klk) 13 (a serine protease involved in regulating inflammation (Ehrenfeld et al., 2018)) 
and α-amilase (a stress-related enzyme (Imura et al., 2016)). Such candidates are upregulated in 
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pathophysiology of the disease (Imura et al., 2016; Ji et al., 2017). Furthermore, recent 
technological advances in clinical neurophysiology suggest that electrogustatometry readings (for 
taste disturbances) and quantitative sensory thresholds (QST) (for detection thresholds) may act as 
sensitive diagnostic tools, or tools that can be used to identify BMS subtypes (Jaaskelainen & 
Woda, 2017).
1.3.  Epidemiology and aetiology of BMS
Depending on the study, BMS prevalence ranges from 0.7% to 15% in the general population 
(Tait et al., 2017), and such variability is due to the lack of objective diagnostic criteria and clear 
distinction between idiopathic and secondary BMS subtypes. In fact, a more recent study 
estimated a lower prevalence of 0.1% when using more stringent criteria for diagnosis (Kohorst et 
al., 2015). Although BMS may affect younger women and men, it is most prevalent at older ages, 
especially in postmenopausal women (Kohorst et al., 2015). Age-adjusted incidence is higher in 
women than men (18.8 vs 3.7/100,000 person-year), with the highest values between 50 to 89 
years of age (maximum of 70.3/100,000 person-year between 70 to 79 years of age) (Kohorst et 
al., 2014). The ratio of male:female BMS is approximately 1:4, and hence the main predictive 
factors for BMS onset are age and sex (Rabiei et al., 2018). Furthermore, sociodemographic 
studies commonly link BMS onset with a stressful life event, particularly unemployment (Adamo 
et al., 2015). Unfortunately the prognosis for such patients is poor, with a significant impact on 
quality of life (QOL) (Kim & Kho, 2018).
Despite much research investigating BMS, its aetiology still remains unclear. It is believed to 
be a multifactorial condition that involves alterations in the expression profile of hormones and 
local neuroactive steroids related to menopause and anxiety states. This, combined with external 
or internal factors (environmental, medical procedures, pharmacological or systemic disease-
related agents), may be deleterious to the function of the nervous system, especially in genetically 
susceptible individuals (Chimenos-Kustner et al., 2017; Jaaskelainen & Woda, 2017). Indeed, 
some authors have categorized BMS risk factors as local and systemic (Table 1) (Bender, 2018); 
local factors can induce oral burning sensation via direct irritation, ischemia or compression of the 
oral tissue, while systemic factors are linked to axonal damage (Jaaskelainen & Woda, 2017). 
Overall, both local and systemic factors may impair neural function (Robinson, 2000; Kang et al., 
2017), and once this occurs, even if the causative factors are removed/treated (secondary BMS 
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replacement therapy, which may be effective at reverting neuropathic changes at early stages, but 
ineffective at later stages when irreversible fibre damage has taken place (Jaaskelainen & Woda, 
2017). Genetic susceptibility should also be further investigated in BMS since polymorphisms in 
IL-1β has been linked to BMS pathogenesis (Guimaraes et al., 2006). Furthermore, some studies 
point to a heightened taste perception and increased number of fungiform papillae on the tongue of 
patients, linking the taste receptor TAS2R38 gene to BMS susceptibility (Kolkka-Palomaa et al., 
2015). Reports of xerostomia and skin disease or symptoms (rosacea, eczema and dry skin) have 
also been strongly linked to BMS (Acharya et al., 2018a). At the CNS, dopamine D2 receptor 
polymorphism C957T has also been associated with BMS aetiology, since such polymorphisms 
result in reduced synaptic dopamine concentrations and a subsequent reduction in pain inhibition 
(Jaaskelainen et al., 2014).
2. Pathophysiology of BMS
There have been major developments in BMS research in recent years, which has resulted in 
classification shifts, particularly from psychogenic to neuropathic (2018; Jaaskelainen, 2018). In 
fact, although anxiety and depression are reported in BMS patients, such conditions commonly 
arise only after BMS onset (Sikora et al., 2018). Moreover, much evidence links BMS with lesions 
and/or dysfunction in the CNS and peripheral nervous system (PNS) (Valenca et al., 2015). In 
addition, both the immune and endocrine systems are closely associated with the onset and 
progression of BMS (Koike et al., 2014). Indeed, allergies (Marino et al., 2009; Acharya et al., 
2018a), and genotypes associated with inflammatory diseases (Guimaraes et al., 2006; Kim et al., 
2017), confer a higher risk for BMS. Overall, the pathophysiology of BMS is complex, with 
multiple mechanisms associated with BMS pathogenesis (Bender, 2018). For the purpose of this 
review, these pathophysiological mechanisms will be discussed under four subject areas; 
neuropathic, immunological, hormonal and psychological (summarised in Figure 1). It is 
important to note that although these mechanisms have been correlated with BMS, much of this 
data is from cross-sectional study analysis. Therefore, it is not clear if these mechanisms are 
present prior to BMS development, or if they manifest as a result of BMS. To overcome this 
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2.1.  Neuropathic 
Much data demonstrate relevant structural and functional changes in both the CNS and PNS of 
patients with BMS (Valenca et al., 2015). Indeed, significant alterations in the structure/function 
of both the hippocampus and the medial prefrontal cortex (mPFC) have been reported in BMS 
patients, compared to healthy individuals (Khan et al., 2014; Wada et al., 2017). Specifically, 
Khan et al., (2014) report an increase in hippocampal gray matter volume (GMV) in BMS 
patients, alongside a decrease in the mPFC (Khan et al., 2014). The latest published data indicate a 
decrease in GMV in the thalamus and middle temporal gyrus of BMS patients when compared to 
control subjects, in addition to a decrease in cerebral blood flow in the middle temporal gyrus and 
insula (Liu et al., 2015; Lee et al., 2019). Such thalamic atrophy may play a key role in BMS 
pathogenesis since this area mediates nociceptive signalling to the cortex, and thalamic lesions are 
associated with chronic pain disorders (Giesecke et al., 2004). In support of this, recent data from 
both Lee et al., (2019) (Lee et al., 2019) and Sinding et al., (2016) (Sinding et al., 2016) correlates 
pain intensity with a decrease in GMV in BMS patients. Moreover, a decrease in cerebral blood 
flow may also correlate with the depressive symptomatology in BMS (Liu et al., 2015).
Functional magnetic resonance imaging (MRI) studies indicate several differences between 
BMS patients and healthy subjects. Indeed, BMS patients exhibit higher functional connectivity 
between the mPFC and areas associated with pain processing (anterior insula cortex and anterior 
cingulate cortex), while in the hippocampus, a decreased connectivity with areas associated with 
working memory and attention (dorsolateral prefrontal cortex) is reported (Khan et al., 2014) 
(Figure 1). Strikingly, those differences increase from morning to afternoon, and correlate with a 
pain/burning state, which may explain the exacerbation of BMS symptoms during the day (Khan 
et al., 2014). Such structural and functional alterations may be linked to anxiety/depression that 
patients endure related to their ongoing pain (Khan et al., 2014).
CNS involvement in BMS is also evident in neurophysiological studies that link this disorder 
to dysfunction in the striatal dopamine system (Hagelberg et al., 2003) (Figure 1). The depletion 
of dopamine in the putamen results in deficient pain inhibition in the trigeminal brainstem 
complex in BMS patients (Hagelberg et al., 2003; Wood, 2008). In support of this, BMS patients 
exhibit low serum levels of neurokinin A, a neuropeptide associated with pain and inflammation 
(Boras et al., 2010). Furthermore, reduced dopaminergic tone may also be associated with the 
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Neural function can be assessed by testing the blink reflex via stimulation of trigeminal nerve 
(cranial nerve V) branches, specifically the supraorbital, mental and lingual nerves. Interestingly, 
with this approach, BMS has been correlated with trigeminal dysfunction in approximately 20% of 
the patients (Jaaskelainen & Woda, 2017). Furthermore, data from Puhakka and colleagues (2016) 
(Puhakka et al., 2016) indicate that BMS is linked to large fibre neuropathy in the form of elevated 
vibratory detection thresholds and enhanced mental nerve blink reflexes. The electrical thresholds 
that elicit the blink reflex are higher in BMS patients than in control subjects, and these finding 
suggest trigeminal tactile A fibre hypofunction (Puhakka et al., 2016; Jaaskelainen & Woda, 
2017). BMS is also related to alterations in taste and sensory systems, as patients frequently report 
bitter, metallic or foul tastes (Jaaskelainen & Woda, 2017; Bender, 2018). Indeed, 
electrogustometry studies indicate that BMS patients have lower taste sensitivity in fungiform and 
foliate taste buds (Braud et al., 2017). Furthermore, Bartoshuk et al., (2005) hypothesise that BMS 
may result from a convergence of pain and taste sensations, and that this may be due to the loss of 
inhibition of the trigeminal nerve due to chorda tympani nerve damage (Bartoshuk et al., 2005). 
Due to the close physiological interaction between the trigeminal and facial nerves, damage to 
either nerve may influence the function of the other (Bartoshuk et al., 2005; Schobel et al., 2012).
BMS has also been linked to peripheral small fibre damage (Figure 1) as shown by 
psychophysical QST or neurophysiological recordings of thermal and pain-evoked potentials, in 
addition to nociceptive reflexes (Jaaskelainen & Woda, 2017). Although the first thermal QST 
found lower tolerance to painful heat stimulus only at the tip of the tongue in BMS (Grushka et al., 
1987), recent studies indicate broader dysfunction of the thermal detection thresholds at the tongue 
mucosa (Puhakka et al., 2016; Hartmann et al., 2017) that correlate with symptom duration 
(Watanabe et al., 2018). In most cases, hypoaesthesia or anaesthesia to innocuous and painful 
thermal stimuli are recorded (Forssell et al., 2002; Puhakka et al., 2016). However, reports 
elsewhere indicate cold hyperalgesia in BMS patients (Yilmaz et al., 2016; Hartmann et al., 2017), 
and despite contradictory findings, the lower reactivity to thermal stimuli may be correlated with a 
reduced volumetric activation throughout the brain (Albuquerque et al., 2006). In terms of the type 
of fibres affected, even though some patients exhibit C fibre hypofunction within the lingual 
nerve, it is more common to detect small myelinated A fibre damage/hypofunction in BMS 
(Puhakka et al., 2016). This suggests that decreased signalling of A fibres results in a deficient 
inhibition of the unmyelinated C fibres, and their continuous signalling may be the cause of the 
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Moura et al., 2018). These findings are supported by neuropathological investigations using oral 
mucosal biopsies from BMS patients, which report a reduced density of epithelial small fibres and 
sub-papillary tongue nerve fibres, while preserving the subepithelial large fibres (Puhakka et al., 
2016). The damage may result from consumption of excessively hot food or beverages, or from 
common dental procedures (Bender, 2018). Dysregulation in mucosal blood flow has also been 
reported in BMS patients, and the increased vasoreactivity in BMS might either result from, or 
affect, the neurovascular microcirculatory unit (Heckmann et al., 2001).
It should be noted that the activity of several receptors located on the tongue is dysregulated in 
BMS. Indeed, the classical G protein-coupled cannabinoid receptor-1 (CB1) is downregulated in 
the tongue epithelia in BMS patients, while cannabinoid receptor-2 (CB2), and the transient 
receptor potential vanilloid 1 (TRPV1) receptor, are upregulated (Yilmaz et al., 2007; Borsani et 
al., 2014). Both receptor types are relevant in the endogenous cannabinoid (endocannabinoid; 
eCB) system, since CB1/2 are “classical” and TRPV1 “non-classical” receptors for eCBs (Di Marzo 
et al., 2015) (discussed in section 4). Likewise, both nerve growth factor (NGF) (Yilmaz et al., 
2007) and artemin (Shinoda et al., 2015) are overexpressed in BMS patients, which is important as 
both of these neurotrophic factors are regulators of TRPV1 expression. The upregulation of 
TRPV1 is particularly relevant since this receptor is commonly activated by noxious heat and 
capsaicin (chili pepper extract), and its expression correlates with ongoing pain symptoms (Yilmaz 
et al., 2007). Similarly, enhanced immunoreactivity of the sensory purinergic receptor P2X3 has 
been reported in BMS, which is primarily expressed on small neurons of sensory ganglia (Beneng 
et al., 2010). A higher density of fungiform papillae usually leads to a higher taste perception that 
may lower tolerance to bitter foods and irritants (Bartoshuk et al., 2005). However, there is still 
controversy regarding dysregulation of its expression; however the distribution of fungiform 
papillae appear asymmetrical on both sides of the tongue in BMS patients, thus indicating an 
asymmetrical innervation (Naud et al., 2018). The taste thresholds within both the fungiform and 
foliate papillae are also impaired in BMS patients (Braud et al., 2017).
2.2.  Immunological
Although few studies have been published focusing on the role of immunological factors in 
BMS, there is growing evidence that a dysregulation of inflammatory mechanisms is a key factor 
in disease onset and development (Figure 1). The dysregulation of several inflammatory 
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(Simcić et al., 2006; Chen et al., 2007; Pekiner et al., 2008; Pezelj-Ribaric et al., 2013; Barry et 
al., 2018a), strengthens the hypothesis of a neuroinflammatory mechanism.
Pro-inflammatory cytokines and chemokines contribute to nociceptive signalling, and their 
expression profiles are altered in neuropathic pain disorders and under conditions of stress 
(Lechner & von Baehr, 2015; Lewis et al., 2017). Indeed, cytokine imbalance may increase the 
risk of depressive symptomatology by modulating central neurotransmitter systems (Liu et al., 
2012). In agreement with this, recent data from a pilot study in our laboratory demonstrate that the 
expression of the pro-inflammatory chemokine IL-8 is enhanced in plasma isolated from BMS 
patients, when compared to control subjects (Barry et al., 2018a). The same study also indicates a 
correlation between the ratio of plasma IL-8:IL-10 and depressive symptomatology in BMS 
patients (Barry et al., 2018a). Interestingly, genetic polymorphisms related to the overexpression 
of the cytokine IL-1β are correlated with BMS development (Guimaraes et al., 2006) and 
psychological asthenia (Kim et al., 2017), and similarly, the expression of the IL-18 cytokine (a 
member of the IL-1 family) is also upregulated in BMS saliva (Ji et al., 2017). Although saliva is a 
promising non-invasive methodology to assess BMS, the data from saliva assessment in BMS is 
more variable, with some studies not identifying differences in salivary cytokines (Boras et al., 
2006; Suh et al., 2009). However, a body of research indicates that the expression of the 
inflammatory cytokines IL-6 (Chen et al., 2007), IL-2 and tumor necrosis factor alpha (TNF-α) 
(Pekiner et al., 2008) are reduced in plasma, while significantly upregulated in saliva (Simcić et 
al., 2006; Pezelj-Ribaric et al., 2013), in BMS cohorts, when compared to healthy subjects. The 
poor classification of the disease, and differences in the methodologies adopted in each study, may 
explain the variability in published data related to cytokine signatures in both BMS plasma and 
saliva.
In the search for BMS biomarkers in saliva, several inflammatory-related molecules have also 
been proposed, with evidence that their expression profiles are altered in BMS; namely Klk (Ji et 
al., 2017) and α-amilase (Imura et al., 2016; Nosratzehi et al., 2017). In addition, the expression of 
membrane-bound mucin 1 (MUC1) in oral epithelial cells (Kang et al., 2017), α-enolase (Ji et al., 
2017) and cystastin (Cabras et al., 2019) are increased in saliva from BMS patients. This is 
particularly relevant since both mucus gel production (Kang et al., 2017) and α-enolase (Ji et al., 
2017) participate in the first line immune defence against pathogens, and a higher neutral cystastin 
reflects a mechanism of defence against ongoing inflammatory processes (Cabras et al., 2019). 
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Among them, NGF is upregulated, and substance P (SP) (Borelli et al., 2010) and calcitonin gene 
related peptide (CGRP) are downregulated (Zidverc-Trajkovic et al., 2009). NGF can trigger mast 
cell degranulation at nerve lesion sites that, in turn, may exacerbate its expression in BMS (Borelli 
et al., 2010). Both SP and CGRP are associated with neurogenic pain and are secreted 
simultaneously. Their reduced expression is indeed a distinct feature from other painful conditions 
(Zidverc-Trajkovic et al., 2009; Borelli et al., 2010). Opiorphin, an inhibitor of enkephalin-
inactivating peptidases (Wisner et al., 2006), is also upregulated in saliva from BMS patients, 
which may represent an adaptive response to chronic pain (Salaric et al., 2017). In addition, 
Boucher et al., (2017) (Boucher et al., 2017) found significant differences in the expression of 
opiorphin in blood samples from BMS patients, which may reflect a systemic dysregulation 
related to environmental stress conditions and psychological distress.
Another poorly investigated pathophysiological mechanism in BMS is the imbalance in the 
eCB system (discussed in section 4), which consists of endogenous ligands for the cannabinoid 
receptors (Storozhuk & Zholos, 2018). Recent data from our laboratory suggests that the 
expression profile of the non-cannabinoid N-acylethanolamine (NAE) molecule 
palmotoylethanolamide (PEA) is increased in plasma isolated from newly diagnosed BMS patients 
compared to healthy subjects, and that plasma PEA levels correlate with pain and depressive 
symptomatology (Barry et al., 2018b). In fact, much evidence indicates that the eCB system can 
regulate nociceptive signalling and the immune response to inflammation, by acting both in the 
CNS and PNS. In addition, the peripheral eCB system is also closely associated with stress and/or 
depressive disorders (Hill et al., 2013; Di Marzo et al., 2015).
The contribution from oxidative stress must also be considered, given that stress-related 
hormonal alterations in post-menopausal BMS patients may affect MUC1 expression and burning 
pain perception (Kang et al., 2017). Stress may, in fact, play a relevant role on BMS 
pathophysiology, since the stress-related enzyme α-amilase is also upregulated in saliva from 
BMS patients (Imura et al., 2016; Nosratzehi et al., 2017). Reports suggesting altered levels of 
reactive oxygen species (ROS) in saliva (Tvarijonaviciute et al., 2017), in addition to alterations in 
total oxidant capacity and biological antioxidant potential as iron-reducing activity in blood 
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2.3.  Hormonal
During menopause, several changes occur in gonadal, adrenal and neuroactive steroid levels 
(Woda et al., 2009), and the higher prevalence of BMS in peri- and postmenopausal women 
(Rabiei et al., 2018) supports the role of female sex hormones in BMS pathogenesis. Indeed, 
hypoestrogenism at menopause is associated with xerostomia and taste alterations (Friedlander, 
2002) as seen in BMS, and the salivary levels of 17β-estradiol in post-menoupausal BMS patients 
correlates with the symptoms of the disorder (Kang et al., 2017). The neuroendocrine stress 
response is controlled via the hypothalamic-pituitary-adrenal (HPA) axis, the activation of which 
promotes an increase in the levels of circulating corticosteroids to impact several systems 
(Pecoraro et al., 2006) (Figure 1). Importantly, chronic stress can disrupt adrenal steroid 
production by impairing the supply of precursors for neuroactive steroids both in the skin, mucosa 
and nervous system (by glial cells in the CNS, and by Schwann cell in the PNS). The lower 
gonadal steroid production inherent to menopause, combined with chronic stress dysregulation, 
can contribute to irreversible neurodegenerative alteration in the PNS (small nerve fibres in oral 
mucosa) and(or) CNS (Woda et al., 2009). Since the production of protective neurosteroids is 
decreased, those regions may be more vulnerable to the action of corticoids (Woda et al., 2009), 
which are increased in saliva from BMS patients (Kim et al., 2012). Since these hormones can 
interact locally with benzodiazepine receptors, it may also explain the localization of pain in BMS 
(Pajot et al., 2003; Dias Fernandes et al., 2009). Furthermore, the over-production of cortisol may 
be a consequence of prolonged anxiety or stress (dysregulation of the HPA axis) (Koike et al., 
2014; Nosratzehi et al., 2017), and both the excessive production and depletion of cortisol may be 
deleterious to neural tissues (Koike et al., 2014).
The adrenal steroid dehydroepiandrosterone (DHEA) is an androgen and estrogen precursor 
associated with the production of male and female sex hormones. Interestingly, levels of this 
hormone are reduced in saliva from BMS patients, suggesting a possible correlation of DHEA 
deficiency with the development of disease (Dias Fernandes et al., 2009). Although there is a clear 
correlation of menopause with BMS onset, it is likely that other factors must be present in 
combination with the hormonal imbalance for the disease onset, since hormone replacement 
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2.4.  Psychological 
Many BMS patients have suffered a stressful life event, either recently or in early life (Lamey 
et al., 2005). While psychological disorders are not considered as causative factors in BMS, 
several studies have associated BMS with psychologic factors (somatization and psychoticism) 
(Yoo et al., 2018), anxiety and depression (Davies et al., 2016). Furthermore, BMS patients 
commonly present with characteristics of type C personality disorders, including fear and neurosis, 
in addition to low levels of novelty seeking (Taiminen et al., 2011; Tokura et al., 2015). 
Individuals with BMS also commonly report a fear of having cancer and commonly overreact to 
trivial stress stimulants (pain catastrophizing) (Rogulj et al., 2014). Indeed, Kim and colleagues 
(2018) report that psychological factors increase the number and severity of BMS symptoms, 
especially in terms of taste disturbances (Kim et al., 2018). Psychologic distress can also influence 
BMS pain perception (Yoshino et al., 2017). It is interesting to note that many personality 
disorders, commonly observed in BMS, are associated with low dopaminergic tone in the CNS 
(Taiminen et al., 2011). Indeed, chronic anxiety and stress promotes alterations in adrenal steroid 
physiology (Woda et al., 2009). In terms of HPA dysfunction, BMS is associated with 
hypercortisolism (Amenabar et al., 2008; Koike et al., 2014), and reports suggest an inverse 
correlation between openness personality traits and stress-related salivary biomarkers, including 
cortisol, in BMS patients (de Souza et al., 2015).
The correlation between BMS and psychological factors is under much investigation, with 
several contradictory reports published. Honda et al., (2019) recently suggested that pain on the 
tongue in elderly female patients with BMS is more related to psychological factors than 
disturbances in mechanical sensitivity, since no QST alterations were determined (Honda et al., 
2019). Also, BMS patients that receive objective information and reassurance about their 
condition tend to be less negative, report lower pain and have a better QOL (Brailo et al., 2016). 
This is supported by the responsiveness to anti-depressants and cognitive behavioural therapy 
(CBT) observed in this patient cohort (discussed in section 3). However, the former is not 
independent of the analgesic activity (Tu et al., 2019), and the latter is usually correlated with 
better coping mechanisms rather than an aetiological cure (Zakrzewska & Buchanan, 2016). 
Moreover, BMS can occur without psychological problems, and furthermore the symptoms in 
BMS do not meet the criteria for a diagnosis of a formal psychiatric disorder (Kim et al., 2018). In 
fact, the psychological distress in BMS may arise only after the pain symptoms, hence being more 
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psychological problems in BMS, leaving the question of a causal or aggravating factor in the 
pathophysiology of this syndrome (Kim & Kho, 2018).
3. BMS therapies
Although there are few data describing the natural course of the disease, the duration of 
symptoms in BMS can prolong for several years. When untreated, a small percentage of patients 
(approximately 3%) may achieve complete remission within five years after the onset of the 
clinical manifestations (Sardella et al., 2006). The treatment of idiopathic BMS is challenging 
since there is limited evidence-based management strategies, and most therapeutic approaches 
yield limited success (Tu et al., 2019). Indeed, data indicate that approximately 30% of the 
patients benefit from neuropathic pain medication (Sardella et al., 2006). Clinically there is a 
reliance on drug therapies that target the clinical manifestations of the disease in combination with 
CBT (McMillan et al., 2016).
The chronic pain, delayed diagnosis and lack of effective treatment greatly impair the QOL of 
BMS patients (Braud & Boucher, 2016). Moreover, patients that have previously experienced 
unsuccessful therapies tend to feel more negative emotions and report fewer positive results from 
new treatments (Varoni et al., 2015). Therefore, there is a need for the clinician to inform and 
reassure the patient to avoid negative thinking and behavioural patterns (Brailo et al., 2016). A full 
understanding of the pathophysiological mechanisms of the disease, together with a better 
diagnostic classification, will facilitate better disease management. As an example, current 
evidence indicates that a CNS-related BMS is more responsive to treatments that target the 
dopaminergic system (Carcamo Fonfria et al., 2017), whereas a PNS-related BMS is more 
responsive to topical administration of the benzodiazepine clonazepam, in addition to nerve 
blockers (Gremeau-Richard et al., 2010).
3.1.  Pharmacological therapy
Several studies have investigated pharmacological approaches to manage BMS, but the 
number of well-designed trials to support pharmacological targets is limited (McMillan et al., 
2016; Liu et al., 2018). Several authors consider tricyclic antidepressants the first-line therapeutic 
choice in BMS due to their wide use in other chronic neuropathic pain conditions (Moore et al., 
2015). α-Lipoic acid (an anti-oxidant), clonazepam (benzodiazepine) or gabapentin (anti-









This article is protected by copyright. All rights reserved
contraindicated or poorly tolerated (Tu et al., 2019). There is also increasing evidence that 
serotonin (5-HT) and noradrenaline (NA) reuptake inhibitors may be considered as an alternative 
treatment, particularly when patients are refractory to other medications. These pharmacological 
agents can act as analgesics by interacting with 5-HT, NA, gamma aminobutyric acid (GABA) and 
enkephalin descending pain signalling (Kim et al., 2014; Mitsikostas et al., 2017). Furthemore, 
capsaicin is also considered for the management of BMS due to its ability to reduce pain by 
decreasing the functionality of TRPV1 nociceptive signalling (Jorgensen & Pedersen, 2017). 
Elsewhere, alternative therapeutic strategies have been explored for BMS, including hormone 
replacement therapies (Tarkkila et al., 2001), other antidepressants/antipsychotics (Takenoshita et 
al., 2017), anaesthetics (Treldal et al., 2016), lafutidine (histamine H2-receptor antagonist) (Toida 
et al., 2009), benzydamine hydrochloride (nonsteroidal anti-inflammatory drug; NSAID) (Sardella 
et al., 1999) and phytotherapeutic compounds (Valenzuela et al., 2016). Unfortunately, there are 
limited controlled clinical studies to support the effectiveness of such compounds. Indeed, many 
studies concerning BMS therapeutics are not standardized, lacking clinically validated pain 
assessment tools specific to BMS, and consensus on how to effectively rate the pain associated 
with BMS. As a consequence, inconsistencies arise when comparing studies (McMillan et al., 
2016).
The most common pharmacological strategies currently employed in BMS, their mechanism 
of action, alongside adverse side effects, are listed in Table 2. From these pharmacological 
strategies, a recent systematic review (de Souza et al., 2018) highlights clonazepam and α-lipoic 
acid as the only pharmacological compounds with the proclivity to significantly reduce BMS 
clinical manifestations compared to placebo in clinical trials. More recently a promising clinical 
study targeted the eCB-like compound PEA. In this study, BMS patients received a sublingual 
dose of ultramicronized PEA (600 mg/twice daily; one sachet every 12 h) for 60 consecutive days. 
During this period, PEA exhibited significant pain-relieving efficacy when compared to the 
placebo group. Moreover, 4 months after ceasing PEA administration, this effect still persisted 
although less pronounced (Ottaviani et al., 2018). Overall, data assessing the cannabinoid system 
as a bone fide therapeutic strategy in BMS are still lacking.
3.2.  Non-pharmacological therapies
Non-pharmacological therapeutic strategies in BMS are diverse, and include low-level laser 
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(Umezaki et al., 2016), acupuncture (Jurisic Kvesic et al., 2015), psychotherapy (Miziara et al., 
2009) and tongue protectors (a transparent polyethylene cover) (López-Jornet et al., 2011). 
Although there is limited data published to date, LLLT poses some promise for reducing pain and 
symptoms in BMS, while being a non-invasive technique with no serious side effects. Indeed, 
LLLT demonstrates analgesic, anti-inflammatory and biostimulatory propensity due to an 
enhancement of 5-HT and β-endorphin synthesis and release, while reducing bradykinin secretion 
and blocking the depolarization of C fibers (Al-Maweri et al., 2017). Also, evidence indicates that 
rTMS, when delivered over the dorsolateral prefrontal cortex, can reduce pain in BMS patients; 
however some patients report headaches as a side effect (Umezaki et al., 2016). Some evidence, 
albeit limited, suggests that acupuncture can improve BMS symptoms (Jurisic Kvesic et al., 2015). 
Overall, CBT has shown beneficial effects in at least one clinical trial (Zakrzewska et al., 2003), 
and its combination with pharmacotherapy can also be beneficial (Femiano et al., 2004). CBT 
focuses on educating BMS patients to parafunctional habits that are detrimental to their condition, 
such as clenching, bruxism and tongue habits (Matsuoka et al., 2017). In addition, tongue 
protectors can be beneficial by controlling parafunctional habits for certain periods during the day 
(López-Jornet et al., 2011). Overall, it is recommended that BMS patients should select oral care 
products that avoid formulations containing alcohol, flavouring agents and other known irritants, 
and should also improve their diet and sleep patterns (Tu et al., 2019).
4. Potential use of cannabinoids for BMS
Cannabinoids include phytocannabinoids synthesised by the annual dioecious plant Cannabis 
sativa L. (C. sativa), endogenous cannabinoid ligands (the eCBs) and synthetic cannabinoid 
compounds (Lu & Mackie, 2016). The most common phytocannabinoids include Δ9-
tetrahydrocannabinol (THC), a psychoactive phytocannabinoid, in addition to cannabinol (CBN) 
(an oxidized metabolite of THC), cannabidiol (CBD), cannabichromene (CBC) and cannabigerol 
(CBG) (Chandra et al., 2017; Booth & Bohlmann, 2019). The eCBs represent a group of lipid 
messengers, synthesized on demand, that can interact with cannabinoid receptors in the eCB 
system. Examples include N-arachidonoylethanolamine (anandamide; AEA), 2-arachidonoyl-
glycerol (2-AG), O-arachidonoyl ethanolamine (virodhamine), N-arachidonoyl dopamine 
(NADA), and 2-arachidonoyl glycerol ether (noladin ether) (Storozhuk & Zholos, 2018). Lastly, 
synthetic cannabinoids are derivates of the phytocannabinoids developed to exert receptor-specific 
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4.1.  Cannabinoid targets
Cannabinoid molecules can exert their action by interacting with the eCB system both in the 
CNS and PNS. This system consists of two “classical” G-coupled protein receptors (GPCRs), CB1 
and CB2, and other “non-classical” receptors, including the TRPV channel, orphan GPCRs 
(GPR119/GPR55) and nuclear peroxisome proliferator-activated receptors (PPARs) (Di Marzo et 
al., 2015) (Figure 2). The “classical” CB1 receptors are distributed predominantly throughout the 
nervous system, and are detected on a diverse array of cells/tissues in the body, including the 
immune, reproductive and digestive systems (Croxford, 2003). In contrast, CB2 receptors are 
found primarily in the periphery, particularly located in cells/tissues of the immune system. 
However, under certain pathological conditions (i.e. nerve injury), CB2 is expressed in some 
populations of neurons (Van Sickle et al., 2005). Thus, CB1 interaction is usually related to 
analgesic effects, while CB2 signalling is commonly related to the immunomodulatory properties 
of these molecules (Pellati et al., 2018). Depending on the structure, cannabinoid molecules have 
different affinities to these receptors, and can interact as agonists, antagonists and (or) inverse 
agonists. Resulting from these complex interactions, cannabinoid molecules can modulate multiple 
intracellular signalling pathways involving adenylyl cyclase (AC), mitogen-activated protein 
kinases (MAPKs), phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB) and voltage-
dependent ion channels (K+, Ca2+, Na+) (Demuth & Molleman, 2006). In terms of the “non-
classical” receptors, TRPV1 is widely expressed in mammalian cells, mediating a variety of 
physiological processes including temperature sensation, pain and inflammation (Yoo et al., 
2019). Several studies have shown that the anti‐inflammatory effects of cannabinoids are also 
mediated by PPAR activation (Paterniti et al., 2013), which inhibit pro-inflammatory signalling 
pathways such as nuclear factor kappa B (NF-B), and promote the expression of anti-
inflammatory mediators (Cheng et al., 2019). Moreover, activation of PPARα might also 
contribute to pain control by triggering TRPV1 signalling and its desensitization (Ambrosino et 
al., 2014). Cannabinoids can also activate GPR55 receptor, which can control inflammation and 
pain (at the periphery), together with processes involved in memory, anxiety and glutamate release 










This article is protected by copyright. All rights reserved
4.2.  Cannabinoid therapeutic properties
Cannabinoid-induced responses are complex due to the pharmacological differences in 
cannabinoid ligands and the involvement of multiple signalling mechanisms governing 
cannabinoid-mediated effects. Evidence shows that the eCB system has an important role in 
nervous system homeostasis and neuroprotection (Xu & Chen, 2015), and the use of cannabinoids 
afford a combination of neuroprotective, anti-inflammatory, antioxidative and anti-apoptotic 
properties (Iuvone et al., 2004; Castillo et al., 2010) (Figure 2). Considering the previously 
described pathophysiological mechanisms of BMS (section 2), such effects of cannabinoids might 
prove beneficial in the treatment of this syndrome and warrants full investigation.
4.2.1. Neuroprotection
Much evidence indicates that cannabinoids have neuroprotective properties in models of 
neurodegeneration. The eCB system is believed to play an important role in synaptic plasticity by 
regulating both excitatory and inhibitory synapses in response to certain events. These 
neurochemical changes contribute to processes such as learning, memory and behavioural 
adaptation (Xu & Chen, 2015). In particular, eCBs released in postsynaptic neurons suppress the 
release of neurotransmitters presynaptically. Therefore, cannabinoids may be beneficial in the 
treatment of BMS by preventing glutamate-induced excitotoxicity (Kano, 2014). In brain ischemic 
injury, cannabinoids can prevent neuronal damage and promote cell survival, by inhibiting 
mitochondrial dysfunction (Ma et al., 2018). In neurodegenerative models, cannabinoids can also 
prevent oxidative stress-related neurotoxicity by modulating endoplasmic reticulum stress 
signalling (Vrechi et al., 2018), reducing ROS accumulation, and lipid peroxidation (Iuvone et al., 
2004). Neuroprotection is also achieved by reducing neurodegeneration caused by 
neuroinflammatory processes (detailed in section 4.2.3) (Esposito et al., 2007). Furthermore, some 
evidence, albeit limited, indicates that cannabinoids stimulate NGF (Velasco et al., 2001) and 
brain-derived neurotrophic factor (BDNF) (D'Souza et al., 2009) production. Considering the 
neuropathic nature of BMS, the neuroprotection afforded by cannabinoids represents a promising 
therapeutic strategy for BMS patients. Moreover, the role for neurotrophins in cannabinoid-
mediated effects (and vice versa) may be critically important given that BMS patients exhibit 
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4.2.2. Neurotransmission
As aforementioned, cannabinoids can also modulate neurotransmission, with associated 
effects on emotion, mood, anxiety and depression (Xu & Chen, 2015). Indeed, an understanding of 
role of the eCB system in depression and anxiety disorders has increased over the last number of 
years, and there is some indication of the therapeutical potential of cannabinoid-based drugs in 
disorders such as anxiety and posttraumatic stress disorders (Chadwick et al., 2019). Adding to the 
inhibion of excitatory glutamatergic system (Colizzi et al., 2016), several studies indicate that 
activation of CB1 receptors can affect a large range of neurotransmitter systems, including 
dopamine, 5-HT, GABA, and NA signalling (Fantegrossi et al., 2018; Mendiguren et al., 2018). 
The eCB system is also a key player in the initiation/termination of HPA axis responses to 
stressful conditions, and much evidence supports the role of the eCB system as a regulator of the 
stress response (Morena et al., 2016). Given the diverse roles of such systems in functional 
connectivity of the nervous system, pain processing, stress, cognition, mood and 
depression/anxiety, the impact of cannabinoids on these systems is critical in the consideration of 
BMS from a therapeutic standpoint. Importantly, our laboratory has shown that the expression of 
the eCB-like compound, PEA, is increased in plasma from BMS patients, and that this correlates 
with depressive symptomatology (Barry et al., 2018b). PEA has potential anti-depressant effects 
(De Gregorio et al., 2019), and the potential therapeutic role of PEA in BMS and neuropathic 
orofacial pain warrants full investigation.
Analgesia is one the principal therapeutic targets of the cannabinoid system, and multiple 
studies have demonstrated the efficacy of cannabinoids in the treatment of neuropathic pain 
(McDonough et al., 2014). Indeed, some evidence indicates that the cannabis-based therapeutic 
Sativex (discussed in section 4.3) can be useful in the management of trigeminal neuropathic 
pain (Gajofatto, 2016).
4.2.3. Anti-inflammatory
Cannabinoids demonstrate anti-inflammatory propensity in various disorders including 
Multiple Sclerosis (MS) (Annunziata et al., 2017), traumatic brain injury (Braun et al., 2018), 
spinal cord injury (Su et al., 2017) and Parkinson's disease (Viveros-Paredes et al., 2017). In these 
studies, the anti-inflammatory action of cannabinoids is predominantly mediated by activation of 
CB2. Furthermore, in vitro data in CNS cells indicate that cannabinoids exert anti-inflammatory 
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et al., 2005) and toll-like receptor (TLR)- (Downer et al., 2011) induced inflammation. Different 
cannabinoids can modulate proinflammatory cytokine and chemokine secretion by targeting 
several inflammatory mechanisms, including NF-B activation (Downer et al., 2011), 
cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and TNF-α (de Lago et al., 
2012). There is growing evidence that several inflammatory mediators are dysregulated in both 
plasma and saliva isolated from BMS patients, when compared to control subjects (Simcić et al., 
2006; Chen et al., 2007; Pekiner et al., 2008; Pezelj-Ribaric et al., 2013; Barry et al., 2018a), 
while polymorphisms in IL-1β are associated with BMS pathogenesis (Guimaraes et al., 2006). 
Therefore, modulation of these, and other proinflammatory molecules, is an important approach to 
consider in the management of BMS.
4.3.  Cannabinoids in the clinic
Several cannabinoid-based therapies, including Sativex, Epidiolex, Marinol and 
Cesamet, have been approved in several countries for use in the clinic for a range of disorders 
(details on indication, mechanism of action and side effects described in Table 3).
Sativex is a combination of THC and CBD (2.7mg THC and 2.5mg CBD/0.1mL; 1:1 ratio) 
approved for the treatment of spasticity and pain in adult patients with MS (Feliu, 2015). The co-
administration of both cannabinoids benefits from the mitigation of THC adverse effects (Vaney et 
al., 2004). Sativex is administered as an oromucosal spray, with the advantage of fast onset of 
action and high bioavailability (Scott et al., 2013). Patients self-titrate the dosage according to 
their need and tolerance of the drug. Interestingly, a THC/CBD spray has been shown to produce 
an improvement in peripheral neuropathic (Serpell et al., 2014). Also, a case study in an individual 
with MS receiving Sativex for spasticity reported complete resolution of trigeminal neuralgia 
episodes and background facial discomfort, which were constantly present before treatment 
(Gajofatto, 2016).
Epidiolex, a purified solution of CBD (100mg/mL), is effective in the treatment of epileptic 
seizures, and has been approved for patients (2 years of age and older) with Lennox-Gastaut and 
Dravet syndromes (Ali et al., 2019). In double-blind placebo-controlled trials, CBD demonstrates 
efficacy in reducing convulsive seizure frequency (Devinsky et al., 2017). Since pure CBD is not 
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Marinol is a pharmaceutical formulation of synthetic THC (2.5mg, 5mg or 10mg soft gelatin 
capsules) indicated for anorexia associated with loss of appetite in AIDs patients, and for the 
treatment of nausea and vomiting in patients undergoing chemotherapy (Badowski & Yanful, 
2018). Phase III studies assessing neuropathic pain symptoms in MS demonstrates a clinically 
relevant decrease in pain during a 16-week Marinol treatment period, when compared to placebo 
(Schimrigk et al., 2017).
Lastly, Cesamet, a synthetic analogue of THC (1mg capsule), is approved in a number of 
countries for the treatment of chemotherapy-induced nausea and vomiting (Zurier & Burstein, 
2016). Additionally, a number of trials have evaluated the efficacy of Cesamet in the treatment of 
pain disorders, including neuropathic pain, chronic non-cancer pain and fibromyalgia (Corey C. 
Tsang, 2016). Reports indicate that Cesamet has a higher bioavailability when compared to 
Marinol (Turcott et al., 2018).
5. Conclusion for future prespectives
BMS remains a true challenge for both patients and healthcare providers. Due to its 
multifactorial etiology and involvement of multiple physiological processes, its definitive 
diagnosis is difficult, and no cure for the disorder has been identified. There is an urgent need for 
well-designed translational research programmes to study the mechansims underlying this 
syndrome, in addition to developing novel therapeutics in this area. Indeed, many studies 
concerning BMS therapeutics are not standardized, lacking clinically validated pain assessment 
tools specific to BMS, and consensus on how to effectively rate the pain associated with BMS. 
Therefore, inconsistencies arise when comparing studies. This review identifies cannabinoid-based 
therapeutics for consideration in the management/treatment of BMS. Given the known 
neuroprotective, anti-inflammatory, antioxidative and anti-apoptotic properties of cannabinoids, a 
full investigation of the cannabinoid system as a bone fide therapeutic strategy in BMS is 
warranted.
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AC – adenylyl cyclase
ACTH – adrenocorticotropic hormone
AEA – anandamide
BDNF – brain-derived neurotrophic factor
BMS – burning mouth syndrome





CBT – cognitive behavioural therapy
CGRP – calcitonin gene related peptide
CNS – central nervous system
COX-2 – cyclooxygenase-2
CRH – corticotropin-releasing hormone
DHEA – dehydroepiandrosterone
eCB – endocannabinoid
GABA – gamma aminobutyric acid
GMV – gray matter volume
GPCRs – G-coupled protein receptors
HPA – hypothalamic-pituitary-adrenal









This article is protected by copyright. All rights reserved
IL – interleukin
iNOS – inducible nitric oxide synthase
Klk13 – kallikrein 13
LLLT – low-level laser therapy
MAPKs – mitogen-activated protein kinases
mPFC – medial prefrontal cortex
MRI – magnetic resonance imaging
MS – multiple sclerosis
MUC1 – mucin 1
NA – noradrenaline
NADA – N-arachidonoyl dopamine
NAE – N-acylethanolamine
NF-B – nuclear factor kappa B
NGF – nerve growth factor
NSAID – nonsteroidal anti-inflammatory drug
PEA – palmotoylethanolamide
PI3K – phosphoinositide 3-kinase
PKB – protein kinase B
PNS – peripheral nervous system
PPARs – peroxisome proliferator-activated receptors
QOL – quality of life
QST – quantitative sensory thresholds
ROS – reactive oxygen species
rTMS – repetitive transcranial magnetic stimulation
SP – substance P
TG – trigeminal nerve
THC – Δ9-tetrahydrocannabinol
TLR – toll-like receptor
TNF-α – tumor necrosis factor alpha
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8. Tables
Table 1: Factors correlated with BMS onset
Local Factors Systemic Factors
 Odontogenic or mucosal disease
 Mechanical or chemical irritation
 Hypersensitivity reactions
 Viral, fungal or bacterial infection
 Xerostomia 
 Parafunctional habits 
 Dentures 
 Candidiasis 
 Nutritional and vitamin deficiencies 
(vitamin B12, folic acid, iron, and zinc)
 Autoimmune, gastrointestinal and endocrine disorders 




Table 2: BMS pharmacological therapies




 Neuropathic pain relief
















 Venlafaxine(Mitsikostas et 
al., 2017)
 Milnacipran
 Chronic pain relief
 Antidepressant
 Activates pain-inhibitory pathways at the CNS 










*Also topical  
(short effect duration) 
 Sedative, anxiolytic, analgesic 
 Agonist for GABA receptors (CNS and PNS*)
 Activates pain-inhibitory pathways at the CNS
 ↓ excitability of peripheral sensory nerve fibres*
 Sedation, somnolence, 
fatigue, dizziness
 Dependence (low risk)
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Anticonvulsants
 Gabapentin**
**Alone or in combination with 
α-Lipoic Acid
 Pain relief
 GABA agonist (CNS)
 ↓ mono-amine neurotransmitters release
 Inhibits voltage-dependent Ca2+ channel subunit 
α2-1/2
 ↓ CNS activity
 Mild adverse effects
 Dose-dependent 
adverse effects
 Somnolence, fatigue, 




 Neuroprotective effect and pain relief
 Antioxidant ( glutathione levels) and free 
radical scavenger
 Stimulate the production of NGF and nerve 
regeneration
  blood glucose levels 
 Modulate inflammatory NF-kB signalling
 Mild adverse effects









  oral burning sensation and neuropathic 
inflammation
 Desensitizes nociceptors via TRPV1 binding in 
peripheral small fibers 
  biosynthesis of neurotransmitters
  neuropeptide stores (CGRP and SP)
 Gastric pain
 Poor patient tolerability













 Oral spray  Cannabinoid 
receptors: CB1, CB2
 G-protein coupled 
receptors: GPR55, 
5HT1A












 Oral solution  G-protein coupled 
receptors: GPR55, 
5HT1A












































Figure 1: Pathophysiological mechanisms in BMS. BMS patients present significant alterations 
at the CNS, including (A) different patterns of connectivity between brain areas associated with 
pain processing, and (B) alterations of the striatal dopaminergic signalling. (C) At the PNS, many 
patients demonstrate trigeminal dysfunction, peripheral small fibre damage and altered activity of 
local receptors. Recent data has shed light on the neuroinflammatory mechanism of this syndrome. 
(D, E) Dysregulation in the production of pro-inflammatory cytokines and chemokines, associated 
with oxidative stress damage, can contribute to, and aggravate, neuropathic pain. Lastly, (F) HPA 
axis dysregulation due to chronic stress, in combination with a lower gonadal steroid production 
inherent to menopause, may also contribute to BMS pathogenesis.
Figure 2: Cannabinoid mechanisms of action relevant to BMS. Both plant-derived 
cannabinoids and eCBs can interact with “classical” and “non-classical” CB receptors. This 
interaction can promote neuronal plasticity, cell survival and modulate neurotransmission, with 
associated effects on pain, anxiety and depression. Cannabinoids also modulate inflammatory and 
oxidative signalling pathways relevant in BMS pathophysiology, including NF-B and MAPK 
signalling.
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